Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Journal of Neuro-Oncology
Published in: Journal of Neuro-Oncology 1/2016

01-08-2016 | Clinical Study

Transforming growth factor-β and stem cell markers are highly expressed around necrotic areas in glioblastoma

Authors: Yasuo Iwadate, Tomoo Matsutani, Seiichiro Hirono, Natsuki Shinozaki, Naokatsu Saeki

Published in: Journal of Neuro-Oncology | Issue 1/2016

Login to get access

Abstract

Invasion into surrounding normal brain and resistance to genotoxic therapies are the main devastating aspects of glioblastoma (GBM). These biological features may be associated with the stem cell phenotype, which can be induced through a dedifferentiation process known as epithelial-mesenchymal transition (EMT). We show here that tumor cells around pseudopalisading necrotic areas in human GBM tissues highly express the most important EMT inducer, transforming growth factor (TGF-β), concurrently with the EMT-related transcriptional factor, TWIST. In addition, the stem cell markers CD133 and alkaline phosphatase (ALPL) were also highly expressed around necrotic foci in GBM tissues. The high expression of TGF-β around necrotic regions was significantly correlated with shorter progression-free survival and overall survival in patients with GBM. High expression of stem cell markers, ALPL, CD133, and CD44 was also correlated with poor outcomes. These results collectively support the hypothesis that tissue hypoxia induces the stem cell phenotype through TGF-β-related EMT and contributes to the poor outcome of GBM patients.
Literature
1.
Aldape K, Zadeh G, von Deimling A et al (2015) Glioblastoma: pathology, molecular mechanisms and markers. Acta Neuropathol 129:829–848CrossRefPubMed
2.
3.
Iwadate Y, Sakaida T, Hiwasa T et al (2004) Molecular classification and survival prediction in human gliomas based on proteome analysis. Cancer Res 64:2496–2501CrossRefPubMed
4.
Phillips HS, Kharbanda S, Chen R et al (2006) Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 9:157–173CrossRefPubMed
5.
Verhaak RGW, Hoadley KA, Purdom E, Wang V, Qi Y et al (2010) Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17:98–110CrossRefPubMedPubMedCentral
6.
Zarkoob H, Taube JH, Singh SK, Mani SA, Kohandel M (2013) Investigating the link between molecular subtype of glioblastoma, epithelial- mesenchymal transition, and CD133 cell surface protein. PLoS One 8:e64169CrossRefPubMedPubMedCentral
7.
Heddleston JM, Li Z, McLendon RE, Hjelmeland AB, Rich JN (2009) The hypoxic microenvironment maintains glioblastoma stem cells and promotes reprogramming towards a cancer stem cell phenotype. Cell Cycle 8:3274–3284CrossRefPubMedPubMedCentral
8.
Cooper LAD, Gutman DA, Chisolm C et al (2012) The tumor microenvironment strongly impacts master transcriptional regulators and gene expression class of glioblastoma. Am J Path. 180:2108–2118CrossRefPubMedPubMedCentral
9.
Charles NA, Holland EC, Gilbertson R et al (2011) The brain tumor microenvironment. Glia. 59:1169–1180CrossRefPubMed
10.
Jensen RL (2009) Brain tumor hypoxia: tumorigenesis, angiogenesis, imaging, pseudoprogression, and as a therapeutic target. J Neurooncol 92:317–335CrossRefPubMed
11.
12.
Bao S, Wu Q, McLendon RE et al (2006) Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444:756–760CrossRefPubMed
13.
Bhat KPL, Balasubramaniyan V, Vaillant B, Ezhilarasan R, Hummelink K et al (2013) Mesenchymal differentiation mediated by NF-kB promotes radiation resistance in glioblastoma. Cancer Cell 24:331–346CrossRefPubMed
14.
Zhang X, Zhang W, Mao XG, Zhen HN, Cao WD, Hu SJ (2013) Targeting role of glioma stem cells for glioblastoma multiforme. Curr Med Chem 20:1974–1984CrossRefPubMed
15.
Murat A, Migliavacca E, Gorlia T, Lambiv WL, Shay T et al (2008) Stem cell-related “self-renewal” signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma. J Clin Oncol 26:3015–3024CrossRefPubMed
16.
Ye X-Z, Xu S-L, Xin Y-H et al (2012) Tumor-associated microglia/macrophages enhance the invasion of glioma stem-like cells via TGF-β1 signaling pathway. J Immunol 189:444–453CrossRefPubMed
17.
Piao Y, Liang J, Holmes L et al (2012) Glioblastoma resistance to anti-VEGF therapy is associated with myeloid cell infiltration, stem cell accumulation, and a mesenchymal phenotype. Neuro-Oncology 14:1379–1392CrossRefPubMedPubMedCentral
18.
19.
20.
21.
Shinojima N, Hossain A, Takezaki T et al (2012) TGF-β mediated homing of bone marrow-derived human mesenchymal stem cells to glioma stem cells. Cancer Res 73:2333–2344CrossRef
22.
Kahlert UD, Nikkhah G, Maciaczyk J (2013) Epithelial-to-mesenchymal (-like) transition as a relevant molecular event in malignant gliomas. Cancer Let. 33:131–138CrossRef
23.
Rong Y, Durden DL, Van Meir EG et al (2006) ‘Pseudopalisading’ necrosis in glioblastoma: a familiar morphologic feature that links vascular pathology, hypoxia, and angiogenesis. J Neuropath Exp Neurol 65:529–539CrossRefPubMed
24.
Bruna A, Darken RS, Rojo F et al (2007) High TGFβ-Smad activity confers poor prognosis in glioma patients and promotes cell proliferation depending on the methylation of the PDGF-B gene. Cnacer Cell 11:147–160CrossRef
25.
Theys J, Jutten B, Habets R et al (2011) E-cadherin loss associated with EMT promotes radioresistance in human tumor cells. Radioth Oncol 99:392–397CrossRef
26.
27.
Hardee ME, Marciscano AE, Medina-Ramirez CM et al (2012) Resistance of glioblastoma-initiating cells to radiation mediated by the tumor microenvironment can be abolished by inhibiting transforming growth factor-β. Cancer Res 72:4119–4129CrossRefPubMedPubMedCentral
28.
Kim Y-H, Yoo K-C, Cui Y-H et al (2014) Radiation promotes malignant progression of glioma cells through HIF-1alpha stabilization. Cancer Lett 354:132–141CrossRefPubMed
29.
Zhou YC, Liu JY, Li J et al (2011) Ionizing radiation promotes migration and invasion of cancer cells through transforming growth factor-beta-mediated epithelial- mesenchymal transition. Int J Radiat Oncol Biol Phys 81:1530–1537CrossRefPubMed
30.
Zhang M, Kleber S, Rohrich M et al (2011) Blockade of TGF-beta signaling by the TGFbetaR-1 kinase inhibitor LY2109761 enhances radiation response and prolongs survival in glioblastoma. Cancer Res 71:7155–7167CrossRefPubMed
31.
Timke C, Zieher H, Roth A et al (2008) Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improve radiation tumor therapy. Clin Cancer Res 14:2210–2219CrossRefPubMed
32.
Mahabir R, Tanino M, Elmansuri A et al (2014) Sustained elevation of Snail promotes glial-mesenchymal transition after irradiation in malignant glioma. Neuro-Oncology 16:671–685CrossRefPubMed
33.
Jain RK (2005) Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307:58–62CrossRefPubMed
34.
Bar EE, Lin A, Mahairaki V, Matsui W, Eberhart CG (2010) Hypoxia increases the expression of stem-cell markers and promotes clonogenicity in glioblastoma neurospheres. Am J Pathol 177:1491–1502CrossRefPubMedPubMedCentral
35.
Evans SM, Judy KD, Dunphy I et al (2004) Hypoxia is important in the biology and aggression of human glial brain tumors. Clin Cancer Res 10:8177–8184
36.
37.
38.
Shahrzad S, Bertrand K, Minhas K, Coomber BL (2007) Induction of DNA hypomethylation by tumor hypoxia. Epigenetics 2:119–129CrossRefPubMed
39.
Skowronki K, Andrews J, Rodenhiser DI, Coomber BL (2014) Genome-wide analysis in human colorectal cancer cells reveals ischemia-mediated expression of motility genes via DNA hypomethylation. PlosOne 9: e103243
40.
Schonberg DL, Lubelski D, Miller TE, Rich JN (2014) Brain tumor stem cells: molecular characteristics and their impact on therapy. Mol Aspects Med 39:82–101CrossRefPubMed
41.
Bechnan J, Isakson P, Joel M et al (2014) Recruited brain tumor-derived mesenchymal stem cells contribute to brain tumor progression. Stem Cells 32:1110–1123CrossRef
Metadata
Title
Transforming growth factor-β and stem cell markers are highly expressed around necrotic areas in glioblastoma
Authors
Yasuo Iwadate
Tomoo Matsutani
Seiichiro Hirono
Natsuki Shinozaki
Naokatsu Saeki
Publication date
01-08-2016
Publisher
Springer US
Published in
Journal of Neuro-Oncology / Issue 1/2016
Print ISSN: 0167-594X
Electronic ISSN: 1573-7373
DOI
https://doi.org/10.1007/s11060-016-2145-6

Other articles of this Issue 1/2016

Journal of Neuro-Oncology 1/2016 Go to the issue

Laboratory Investigation

An allograft mouse model for the study of hearing loss secondary to vestibular schwannoma growth

Laboratory Investigation

Differential DNA methylome profiling of nonfunctioning pituitary adenomas suggesting tumour invasion is correlated with cell adhesion

Clinical Study

Prevalence and profile of cognitive impairment in adult glioma: a sensitivity analysis

Laboratory Investigation

Development of a transplantable glioma tumour model from genetically engineered mice: MRI/MRS/MRSI characterisation

Clinical Study

Single-agent erlotinib versus oral etoposide in patients with recurrent or refractory pediatric ependymoma: a randomized open-label study

Clinical Study

Osteopontin in cerebrospinal fluid as diagnostic biomarker for central nervous system lymphoma